Orbsen Therapeutics Receives Approval from European Regulators for Clinical Trial of Breakthrough Cell Therapy for Diabetic Kidney Disease

NEW YORK–(BUSINESS WIRE)–Orbsen Therapeutics (www.orbsentherapeutics.com) breakthrough stromal cell immunotherapy, OBRCEL-M™, developed as part of NEPHSTROM, a European Union Horizon 2020-funded research project coordinated by NUI Galway, has been approved to begin testing in a randomised, double blind, and placebo-controlled European clinical trial to treat diabetic kidney disease.

2018-03-06T20:17:32+00:00 February 22nd, 2018|